Publication | Open Access
A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma
43
Citations
46
References
2022
Year
This study was registered in ClinicalTrials.gov (NCT03111732).
| Year | Citations | |
|---|---|---|
Page 1
Page 1